DIFFUSE CUTANEOUS SYSTEMIC SCLEROSIS
Clinical trials for DIFFUSE CUTANEOUS SYSTEMIC SCLEROSIS explained in plain language.
Never miss a new study
Get alerted when new DIFFUSE CUTANEOUS SYSTEMIC SCLEROSIS trials appear
Sign up with your email to follow new studies for DIFFUSE CUTANEOUS SYSTEMIC SCLEROSIS, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
Drug trial tests new hope for Hard-to-Treat skin and lung disease
Disease control TerminatedThis trial tested an investigational drug called HZN-825 in adults with a severe form of systemic sclerosis, a disease that causes skin thickening and can damage the lungs. About 300 participants received either the drug or a placebo for one year to see if it could improve lung f…
Matched conditions: DIFFUSE CUTANEOUS SYSTEMIC SCLEROSIS
Phase: PHASE2 • Sponsor: Amgen • Aim: Disease control
Last updated Mar 30, 2026 14:31 UTC
-
Drug trial aims to slow lung damage in rare autoimmune disease
Disease control TerminatedThis extension study followed patients who completed a previous trial to continue testing the experimental drug HZN-825 for an additional year. It aimed to see if the drug could help preserve lung function in people with diffuse cutaneous systemic sclerosis, a rare autoimmune dis…
Matched conditions: DIFFUSE CUTANEOUS SYSTEMIC SCLEROSIS
Phase: PHASE2 • Sponsor: Amgen • Aim: Disease control
Last updated Mar 23, 2026 15:19 UTC